CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 96 enrolled
Drug / intervention
Adalimumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01768858
NCT01768858N/ACompleted
CompareCT.gov

Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice

AbbVie·observational·Posted Jan 16, 2013·Updated Jan 28, 2019

In Brief

An observational study evaluating Adalimumab for Rheumatoid Arthritis and 5 related conditions. Completed, enrolled 96 participants.

Detailed Summary

The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's disease (CD) and ulcerative colitis (UC) patients' adherence attitudes (beliefs) to maintenance therapy with adalimumab monotherapy or combination therapy with methotrexate (in participants with RA) and to investigate whether there were correlations between such beliefs and adherence to maintenance treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease, Ulcerative Colitis, Plaque Psoriasis
Countries--
CollaboratorsRaffeiner GmbH

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2013
Enrollment StartFeb 5, 2013
Primary CompletionAug 13, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.5 years ago

Interventions

Adalimumabdrug

Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen